SARS-CoV-2 ORF7a Antibody (3C9)

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-13521

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP3-13521
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

SARS-CoV, SARS-CoV-2

Applications

Immunocytochemistry/ Immunofluorescence, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 3C9

Concentration

Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.

View all SARS-CoV-2 ORF7a Antibodies »

Product Specifications

Immunogen

The immunogen used to generate this antibody corresponds to SARS-CoV ORF7a protein (16-111 a.a.).

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Description

Centrifuge briefly prior to opening.

Scientific Data Images for SARS-CoV-2 ORF7a Antibody (3C9)

Western Blot: SARS-CoV-2 ORF7a Antibody (3C9) [NBP3-13521]

Western Blot: SARS-CoV-2 ORF7a Antibody (3C9) [NBP3-13521]

Western Blot: SARS-CoV-2 ORF7a Antibody (3C9) [NBP3-13521] - Non-infected (-) and infected (+, 48h pl MOI 0.01) Caco2 whole cell extracts were separated by SDS-PAGE, and the membrane was blotted with SARS-CoV / SARS-CoV-2 (COVID-19) ORF7a antibody [3C9] (NBP3-13521) diluted at 1:1000.
Immunocytochemistry/ Immunofluorescence: SARS-CoV-2 ORF7a Antibody (3C9) [NBP3-13521]

Immunocytochemistry/ Immunofluorescence: SARS-CoV-2 ORF7a Antibody (3C9) [NBP3-13521]

Immunocytochemistry/Immunofluorescence: SARS-CoV-2 ORF7a Antibody (3C9) [NBP3-13521] - SARS-CoV / SARS-CoV-2 (COVID-19) ORF7a antibody [3C9] detects SARS-CoV / SARS-CoV-2 (COVID-19) ORF7a protein by immunofluorescent analysis. Sample: Mock and transfected 293T cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: SARS-CoV / SARS-CoV-2 (COVID-19) ORF7a stained by SARS-CoV / SARS-CoV-2 (COVID-19) ORF7a antibody [3C9] (NBP3-13521) diluted at 1:200. Blue: Fluoroshield with DAPI.
Western Blot: SARS-CoV-2 ORF7a Antibody (3C9) [NBP3-13521]

Western Blot: SARS-CoV-2 ORF7a Antibody (3C9) [NBP3-13521]

Western Blot: SARS-CoV-2 ORF7a Antibody (3C9) [NBP3-13521] - WB analysis of SARS-CoV-infected Vero E6 cells harvested at different time points postinfection using NBP3-13521 SARS-CoV / SARS-CoV-2 (COVID-19) ORF7a antibody [3C9].
View 2 more images

Applications for SARS-CoV-2 ORF7a Antibody (3C9)

Application
Recommended Usage

Western Blot

1:500-1:3000
Application Notes
ICC/IF-Assay dependent

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

PBS

Preservative

No Preservative

Concentration

Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: SARS-CoV-2 ORF7a

SARS-CoV-2 Open Reading Frame 7a (ORF7a) is one of the nine downstream accessory protein open reading frames of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19 (1). SARS-CoV-2 ORF7a is a type I transmembrane protein with a 121 amino acid (aa) sequence and a theoretical molecular weight of 13.7 kDa (2, 3). ORF7a localizes mostly on the Golgi apparatus but also presents on the cell surface (4). The N-terminal domain of ORF7a is comprised of 7 beta-strands that form 2 beta-sheets, arranged by an immuno-globulin-like beta-sandwich fold (2, 5). The aa sequence alignment of SARS-CoV and SARS-CoV-2's ORF7a has 85.2% sequence identity and 95.9% sequence similarity (3).

Similar to its role in SARS-CoV, ORF7a of SARS-CoV-2 is an inhibitor of the host tetherin bone marrow stromal antigen-2 (BST-2) (2, 4). Functionally, ORF7a binds to BST-2, inhibiting its viral restriction activity by blocking glycosylation (2, 4).

References

1. Michel, C. J., Mayenr, C., Poch, O., & Thompson, J. D. (2020). Characterization of accessory genes in coronavirus genomes. Virology journal. https://doi.org/10.1186/s12985-020-01402-1

2. UniProt (P0DTC7)

3. Yoshimoto F. K. (2020). The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. The protein journal. https://doi.org/10.1007/s10930-020-09901-4

4. Taylor, J. K., Coleman, C. M., Postel, S., Sisk, J. M., Bernbaum, J. G., Venkataraman, T., Sundberg, E. J., & Frieman, M. B. (2015). Severe Acute Respiratory Syndrome Coronavirus ORF7a Inhibits Bone Marrow Stromal Antigen 2 Virion Tethering through a Novel Mechanism of Glycosylation Interference. Journal of virology. https://doi.org/10.1128/JVI.02274-15

5. Nelson, C. A., Pekosz, A., Lee, C. A., Diamond, M. S., & Fremont, D. H. (2005). Structure and intracellular targeting of the SARS-coronavirus Orf7a accessory protein. Structure (London, England : 1993). https://doi.org/10.1016/j.str.2004.10.010

Alternate Names

2019-nCoV ORF7a, 2019-nCoV ORF7a Protein, Accessory Protein 7a, COVID-19 Accessory Protein 7a, COVID-19 ORF7a, COVID-19 Protein U122, COVID-19 Protein X4, Human coronavirus ORF7a Protein, ORF7a Protein, Protein U122, Protein X4, SARS-CoV-2 Accessory Protein 7a, SARS-CoV-2 Protein U122, SARS-CoV-2 Protein X4

Gene Symbol

ORF7a

Additional SARS-CoV-2 ORF7a Products

Product Documents for SARS-CoV-2 ORF7a Antibody (3C9)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for SARS-CoV-2 ORF7a Antibody (3C9)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.